Back to GetFilings.com



Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 10-Q
 
x
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2002
 
OR
 
¨
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from              to             
 
Commission File Number 000-31147
 
DELTAGEN, INC.
(Exact name of Registrant as specified in its charter)
 
Delaware
 
94-3260659
(State or other jurisdiction of
Incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
740 Bay Road, Redwood City, CA
 
94063
(Address of principal executive offices)
 
(Zip code)
 
(650) 569-5100
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 
YES x    NO ¨
 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:
 
Common Stock $0.001 par value
 
40,936,370

 
Class
 
Outstanding at November 8, 2002
 


Table of Contents
 
DELTAGEN, INC.
 
FORM 10-Q
 
QUARTERLY REPORT
 
TABLE OF CONTENTS
 
PART I—FINANCIAL INFORMATION
 
Item 1.
    
3
      
3
      
4
      
5
      
6
Item 2.
    
12
Item 3.
    
33
Item 4.
    
34
 
PART II—OTHER INFORMATION
 
Item 1.
    
34
Item 2.
    
34
Item 3.
    
34
Item 4.
    
34
Item 5.
    
34
Item 6.
    
34
  
36
  
37
 

2


Table of Contents
 
PART I.    FINANCIAL INFORMATION
 
Item 1.    Financial Statements
 
DELTAGEN, INC.
 
CONSOLIDATED BALANCE SHEETS
(unaudited)
(in thousands, except share data)
 
    
September 30, 2002

    
December 31, 2001

 
Assets
                 
Current assets:
                 
Cash and cash equivalents
  
$
28,415
 
  
$
61,363
 
Marketable securities
  
 
21,253
 
  
 
15,118
 
Accounts receivable, net
  
 
769
 
  
 
2,511
 
Prepaid expenses and other current assets
  
 
3,889
 
  
 
2,207
 
    


  


Total current assets
  
 
54,326
 
  
 
81,199
 
Property, plant and equipment, net
  
 
36,606
 
  
 
16,672
 
Goodwill
  
 
—  
 
  
 
1,788
 
Intangible assets, net
  
 
6,249
 
  
 
3,479
 
Notes receivable from related parties
  
 
995
 
  
 
495
 
Restricted cash
  
 
3,838
 
  
 
2,869
 
Other assets
  
 
2,730
 
  
 
2,548
 
    


  


Total assets
  
$
104,744
 
  
$
109,050
 
    


  


Liabilities and Stockholders’ Equity
                 
Current liabilities:
                 
Accounts payable
  
$
8,877
 
  
$
4,131
 
Accrued liabilities
  
 
7,193
 
  
 
5,864
 
Current portion of capital lease obligations
  
 
21
 
  
 
11
 
Current portion of loans payable
  
 
14,008
 
  
 
2,382
 
Current portion of deferred revenue
  
 
13,838
 
  
 
7,257
 
    


  


Total current liabilities
  
 
43,937
 
  
 
19,645
 
Capital lease obligations, less current portion
  
 
9
 
  
 
28
 
Loans payable, less current portion
  
 
2,374
 
  
 
3,059
 
Other long-term liabilities
  
 
990
 
  
 
990
 
Deferred credit
  
 
2,953
 
  
 
—  
 
Deferred revenue, less current portion
  
 
2,910
 
  
 
1,657
 
    


  


Total liabilities
  
 
53,173
 
  
 
25,379
 
    


  


Stockholders’ equity:
                 
Common stock, $0.001 par value:
                 
Authorized: 75,000,000 shares, issued and outstanding: 40,908,740 and 32,077,012 shares at September 30, 2002 and December 31, 2001, respectively
  
 
41
 
  
 
32
 
Additional paid-in capital
  
 
238,615
 
  
 
186,595
 
Unearned stock-based compensation
  
 
(1,018
)
  
 
(3,019
)
Notes receivable from stockholders
  
 
(805
)
  
 
(805
)
Accumulated deficit
  
 
(185,262
)
  
 
(99,132
)
    


  


Total stockholders’ equity
  
 
51,571
 
  
 
83,671
 
    


  


Total liabilities and stockholders’ equity
  
$
104,744
 
  
$
109,050
 
    


  


 
The accompanying notes are an integral part of these consolidated financial statements.

3


Table of Contents
 
DELTAGEN, INC.
 
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
 
    
Three months ended September 30,

    
Nine months ended September 30,

 
    
2002

    
2001

    
2002

    
2001

 
Contract revenue
  
$
4,409
 
  
$
2,265
 
  
$
12,943
 
  
$
7,451
 
    


  


  


  


Costs and expenses:
                                   
Research and development
  
 
20,821
 
  
 
13,080
 
  
 
58,736
 
  
 
31,688
 
Selling, general and administrative
  
 
5,316
 
  
 
4,472
 
  
 
14,388
 
  
 
12,654
 
Impairment of goodwill and other long-lived assets
  
 
26,793
 
  
 
—  
 
  
 
26,793
 
  
 
—  
 
    


  


  


  


Total costs and expenses
  
 
52,930
 
  
 
17,552
 
  
 
99,917
 
  
 
44,342
 
    


  


  


  


Loss from operations
  
 
(48,521
)
  
 
(15,287
)
  
 
(86,974
)
  
 
(36,891
)
Interest income
  
 
686
 
  
 
915
 
  
 
1,566
 
  
 
3,887
 
Interest expense
  
 
(325
)
  
 
(262
)
  
 
(722
)
  
 
(561
)
    


  


  


  


Net loss
  
$
(48,160
)
  
$
(14,634
)
  
$
(86,130
)
  
$
(33,565
)
    


  


  


  


Net loss per common share, basic and diluted
  
$
(1.19
)
  
$
(0.50
)
  
$
(2.34
)
  
$
(1.16
)
    


  


  


  


Weighted average shares used in computing net loss per common share, basic and diluted
  
 
40,517
 
  
 
29,504
 
  
 
36,865
 
  
 
28,959
 
    


  


  


  


 
The accompanying notes are an integral part of these consolidated financial statements.

4


Table of Contents
 
DELTAGEN, INC.
 
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)
 
    
Nine months ended
September 30,

 
    
2002

    
2001

 
Cash flows from operating activities:
                 
Net loss
  
$
(86,130
)
  
$
(33,565
)
Adjustments to reconcile net loss to net cash used in operating activities:
                 
Depreciation and amortization
  
 
5,256
 
  
 
1,872
 
Amortization of equipment under capital lease
  
 
21
 
  
 
—  
 
Amortization of warrants issued in connection with loans
  
 
55
 
  
 
35
 
Amortization of intangible assets
  
 
3,203
 
  
 
224
 
Amortization of unearned stock-based compensation expense
  
 
1,344
 
  
 
3,006
 
Amortization of premium (discount) on marketable securities
  
 
134
 
  
 
(637
)
Lease loss
  
 
—  
 
  
 
1,312
 
Write-off of in-process research and development costs
  
 
110
 
  
 
907
 
Impairment of goodwill and other long-lived assets
  
 
26,793
 
  
 
—  
 
Changes in operating assets and liabilities, net of effects of acquisitions:
                 
Accounts receivable
  
 
1,742
 
  
 
(1,206
)
Prepaid expenses and other current assets
  
 
(1,274
)
  
 
(1,110
)
Other assets
  
 
19
 
  
 
(2,899
)
Accounts payable
  
 
(880
)
  
 
1,028
 
Accrued expenses
  
 
481
 
  
 
628
 
Deferred revenue
  
 
7,834
 
  
 
(400
)
    


  


Net cash used in operating activities
  
 
(41,292
)
  
 
(30,805
)
    


  


Cash flows from investing activities:
                 
Purchase of marketable securities
  
 
(11,269
)
  
 
(39,364
)
Maturities of marketable securities
  
 
5,000
 
  
 
55,000
 
Acquisition of property, plant and equipment
  
 
(1,729
)
  
 
(4,434
)
Acquisition of leasehold improvements
  
 
(17,001
)
  
 
(318
)
Increase in restricted cash
  
 
(969
)
  
 
(2,707
)
Issuance of notes receivable
  
 
(500
)
  
 
(260
)
Acquisition of Arcaris, Inc., net of cash acquired
  
 
—  
 
  
 
(450